Hematological malignancies and molecular targeting therapy

• Published in: European journal of pharmacology Vol. 862; p. 172641
• Main Author: Shimada, Akira
• Format: Journal Article
• Language: English
• Published: Netherlands Elsevier B.V 05.11.2019
• Subjects: Acute lymphoblastic leukemia; Acute myeloid leukemia; Chronic myeloid leukemia; Combined Modality Therapy - methods; Disease-Free Survival; Hematologic Neoplasms - etiology; Hematologic Neoplasms - mortality; Hematologic Neoplasms - therapy; Humans; Immunotherapy, Adoptive - methods; Molecular Targeted Therapy - methods; Molecular targeting therapy; Myeloproliferative neoplasm; Prognosis; Protein Kinase Inhibitors - pharmacology; Protein Kinase Inhibitors - therapeutic use; Protein-Tyrosine Kinases - antagonists & inhibitors; Protein-Tyrosine Kinases - genetics; Protein-Tyrosine Kinases - immunology; Randomized Controlled Trials as Topic; Receptors, Chimeric Antigen - immunology; Tyrosine kinase inhibitor; Chronic myeloid leukemia; Acute lymphoblastic leukemia; Molecular targeting therapy; Tyrosine kinase inhibitor; Acute myeloid leukemia; Myeloproliferative neoplasm
• ISSN: 0014-2999; 1879-0712
• DOI: 10.1016/j.ejphar.2019.172641

Recent genetic analysis using next-generation sequencing (NGS) vastly improved the understanding of molecular mechanism of hematological malignancies. Many molecular targeting drugs have since been used in the clinic, which is timely as clinical outcomes using conventional chemotherapy and hematopoietic stem cell transplantation (HSCT) reached a plateau. The first memorable success in this field was imatinib, a first-generation tyrosine kinase inhibitor (TKI), which has been applied in chronic myeloid leukemia (CML) since 2001. Imatinib drastically changed CML treatment and many CML patients no longer require HSCT. Recently, the second generation TKIs, dasatinib, nilotinib, and ponatinib, have also been available for CML patients. Acute lymphoblastic leukemia (ALL) is sub-categorized based on cytogenetic or molecular genetic abnormalities. Chemotherapy and HSCT combined with TKI improved the event-free survival rate from 20% to 80% in Philadelphia (Ph) chromosome-positive ALL. Reportedly, another Ph-like ALL subgroup with poor prognosis can also be treated by TKIs; additionally, cell therapies that include bispecific T-cell engagers or chimeric antigen receptor (CAR)-T therapy are emerging. Acute myeloid leukemia (AML) is a heterogenous disease and FMS-like related tyrosine kinase-3 (FLT3)-internal tandem duplication, is the most robust marker for poor prognosis. Several first-generation TKIs have been studied for clinical use. Notably, chemotherapy plus midostaurin improved survival compared with chemotherapy alone. Therefore, midostaurin was approved to treat adult AML patients with FLT3-ITD in 2017. Gemtuzumab ozogamicin, a selective anti-CD33 antibody–calicheamicin conjugate, is approved for clinical practice. Many molecular targeting agents are now being used for hematological malignancies.